RussianPatents.com

Method of obtaining of anthracic protective antigen

IPC classes for russian patent Method of obtaining of anthracic protective antigen (RU 2340356):
Another patents in same IPC classes:
Immunogenic composition (versions) based on recombinant intracellular pathogen Immunogenic composition (versions) based on recombinant intracellular pathogen / 2337707
Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene.
Proteins causing alternated immunogenic response and methods for their preparing and using Proteins causing alternated immunogenic response and methods for their preparing and using / 2311458
Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine.
Method for preparing nontoxic anti-anthrax vaccine Method for preparing nontoxic anti-anthrax vaccine / 2287581
Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax.
Associated vaccine against anthrax and plague in cattle / 2286173
The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.
Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis / 2270865
Invention relates to a method for preparing an immunogenic polypeptide inducing immune response that represents the protective response against infection with Bacillus anthracis. Proposed immunogenic polypeptide comprises from one to three domains of the full-scale Protective Antigen (PA) from B. anthracis or their variants and at least one of indicated domains represents domain 1 or domain 4 from PA or its variant. These variants of immunogenic polypeptide and full-scale PA are produced as result of expression in E. coli. Also, invention proposes a vector for expression in bacterial cells that comprises nucleic acid encoding abovementioned immunogenic polypeptide. Also, invention the developed method for prophylaxis of infection caused by B. anthracis based on administration of sufficient amount of immunogenic polypeptide. Also, invention proposes a vaccine for prophylaxis of infection caused by B. anthracis that comprises the effective amount of immunogenic polypeptide and a suitable carrier. Invention provides preparing the effective agent used for prophylaxis of infection caused by B. anthracis.
Method for production of immune serum to virulent strain bacillus anthracis antigen Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
Isolation of high-molecular somatic anthrax antigen Isolation of high-molecular somatic anthrax antigen / 2230570
The invention relates to medical Microbiology and can be used to study the antigenic structure of Bacillus anthracis and identification of different genotypes Century anthracis
A combined vaccine against anthrax in animals A combined vaccine against anthrax in animals / 2220742
The invention relates to veterinary biology and immunology, in particular to the production and application of biological preparations for vaccination of animals
Integrated prevention of anthrax Integrated prevention of anthrax / 2216349
The invention relates to medicine, infectious diseases and can be used for integrated prevention of anthrax
Globulin protivoseborainey horse dry Globulin protivoseborainey horse dry / 2214836
The invention relates to the field of biotechnology and immunology, and can be used to stabilize the physicochemical and biologic properties globulin protivovirusnogo
Method for production of immune serum to virulent strain bacillus anthracis antigen Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis / 2270865
Invention relates to a method for preparing an immunogenic polypeptide inducing immune response that represents the protective response against infection with Bacillus anthracis. Proposed immunogenic polypeptide comprises from one to three domains of the full-scale Protective Antigen (PA) from B. anthracis or their variants and at least one of indicated domains represents domain 1 or domain 4 from PA or its variant. These variants of immunogenic polypeptide and full-scale PA are produced as result of expression in E. coli. Also, invention proposes a vector for expression in bacterial cells that comprises nucleic acid encoding abovementioned immunogenic polypeptide. Also, invention the developed method for prophylaxis of infection caused by B. anthracis based on administration of sufficient amount of immunogenic polypeptide. Also, invention proposes a vaccine for prophylaxis of infection caused by B. anthracis that comprises the effective amount of immunogenic polypeptide and a suitable carrier. Invention provides preparing the effective agent used for prophylaxis of infection caused by B. anthracis.
Associated vaccine against anthrax and plague in cattle / 2286173
The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.
Method for preparing nontoxic anti-anthrax vaccine Method for preparing nontoxic anti-anthrax vaccine / 2287581
Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax.
Proteins causing alternated immunogenic response and methods for their preparing and using Proteins causing alternated immunogenic response and methods for their preparing and using / 2311458
Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine.
Immunogenic composition (versions) based on recombinant intracellular pathogen Immunogenic composition (versions) based on recombinant intracellular pathogen / 2337707
Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene.
Method of obtaining of anthracic protective antigen / 2340356
Plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining.
Method for immunoprophylaxis of experimental pseudocholera with entrapped antigens burkholderia pseudomallei / 2373955
Invention refers to medicine, particularly to microbiology and immunology and can be used for immunoprophylaxis of pseudocholera. The method involves antigen pretreatment to mice followed by infection and estimating level of protectivity. Antigens Burkholderia pseudomallei are chosen of superficial antigenic fractions: D, C, F, J, H. Herewith the antigen solution in amount 1.5 ml is mixed with phosphatidyl choline approximately 40 mg and cholesterol in the ratio 7:3 to produce liposomes.
Method for increase of melioidosis antigens protectivity by cytokines / 2376031
Invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified.
Method for producing diagnostic anthrax allergen / 2415941
Method provides recovery of a diagnostic anthrax allergen directly from a concentrated suspension of vegetative cells of a vaccine strain Bac. anthracis STI-1. The strain is grown on a nutrient medium based on a muriatic hydrolyzate of a fish flour by deep cultivation. The produced bacterial mass is washed in a separator to produce the concentrated suspension of vegetative cells. An allergenic protein fraction is recovered by alkaline hydrolysis, and the prepared hydrolyzate is fractioned. A protein allergen fraction is recovered from a supernatant of the recovered fraction by fractioning with an acetic acid solution; further the precipitation containing an end product is dissolved, dialyzed to produce a purified anthrax protein allergen. The preparation is presented in liquid and lyophilised forms.

FIELD: medicine; biotechnologies.

SUBSTANCE: plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining.

EFFECT: stable obtaining of a native anthracic protective antigen with the activity in "РДП" more that 100 EA·ml-1 and reduction of time and stages of reception of the sterile concentrated protective antigen with the activity in "РДП" more that 200 EA·ml-1.

3 tbl, 2 ex

 

The invention relates to the microbiological industry, and specifically to a technology for anthrax protective antigen (PA), in particular to the anthrax vaccine, and can be used in medicine and veterinary medicine for the prophylaxis of anthrax.

The invention allows to reproducibly obtain native PA activity in the reaction diffusion precipitation (RDP) in the gel more than 100 EA·ml-1to reduce the time and number of process steps of obtaining sterile concentrated PA.

Anthrax PA is used to obtain two types of vaccines: anthrax purified adsorbed chemical and combination of liquid and dry (one of the components which it is), immunological and physicochemical parameters that satisfy the requirements of the national authority of control of medical immunobiological preparations (mibp) to these vaccines.

A method of obtaining anthrax PA at deep anaerobic cultivation of strain B.antracis on a nutrient medium containing sodium bicarbonate when aeration of the culture fluid with an inert gas(patent RU 2223114 C2, 10.02.2004). This method is used in the preparation of anthrax vaccine adsorbed purified chemical liquid, comprising the following the steps:

preparation of master seed culture production strain STI-1;

preparation of production nutrient medium;

getting native culture strain STI-1;

getting native PA;

obtaining sterile PA, including the separation of native PA separator SA-1-02-575, concentrating on the installation UFA-4,0, gross, subtle, and sterilizing filtration through a filter paper of "blue ribbon", the filter membrane IFA # 2 and IPA No. 1;

sorption sterile concentrated PA gel aluminium hydroxide;

stabilization formalin solution and washing sorbed PA;

breeding sorbed concentrated PA, bottling;

the quality control of the obtained sorbed concentrated PA.

The disadvantage of the above method is the low reproducibility in obtaining native PA in fermenters with desired activity of PA in the reaction diffusion precipitation 100 EA·ml-1and more. In addition, when the allocation of PA from the culture fluid used method of separation that time longer and has the following disadvantages (human development Report. Improving the technology of production of chemical anthrax vaccine Architect. RF 23527 - inv. No. 30353, 1997. - P.28):

the complexity of the operation (vibration, noise, the necessity of disassembly and cleaning) system;

effects on microbial culture centrifugal force, differential pressure and hydrodynamic blow;

the lack of sealing and ensure aseptic process conditions.

In addition, it is known that when growing microbial population anthrax vaccine strain STI-1 in the presence of bicarbonate ion to be added to the beginning of the cultivation, increases the proportion of cells with structural damage pag gene under conditions of unbalanced growth (Sirard J.C., Mocr M, Fonet A. Tne three Bacillus anthracis taxin genesare coordinately regulated by bicarbonate-heat and temperature. / J. Bacterid / - 1962/ - vol.52, p.632-645), which affects the production of antigen.

Object of the invention is stable reception of native anthrax PA with high activity, reducing the time of obtaining sterile concentrated PA with high activity.

The problem is solved by changing the moment of introduction of the sodium bicarbonate solution in the process of cultivating and receiving the sterile concentrated PA method for ultra - and microfiltration.

The possibility of practical use of the claimed invention, the following examples.

Example 1. Change the time of the introduction of the inducer of the synthesis of PA-solution of sodium bicarbonate (NaHCO3).

It is known that when growing microbial population vaccine, sibireyazvenne the th strain STI-1 in the presence of bicarbonate ion, added to the beginning of the cultivation, increases the proportion of cells with structural damage pag gene under conditions of unbalanced growth (Sirard J.C., Mocr M., Fonet A. Tne three Bacillus anthracis taxin genesare coordinately regulated by bicarbonate-heat and temperature. / J. Bacterid / - 1962 / - vol.52, p.632-645).

To reduce the negative impact on the development of microbial culture in an initial growth phase, caused by the presence in the PS of sodium bicarbonate, it is advisable to introduce inductor (NaHCO3synthesis PA in the dynamics of cultivation on 6...8 hours of growth, which is controlled by the concentration of glucose in the medium and the pH value of the culture fluid. Sodium bicarbonate activates gene expression happy determining the synthesis of PA, late lag phase and during the exponential phase of growth.

Dynamics of microbial populations anthrax vaccine strain and accumulation of PA on the existing method (based on five cycles of fermentation technology are presented in table 1, the claimed method in table 2 (based on 10 cycles of fermentation).

As can be seen from the results shown in tables 1 and 2, the introduction of sodium bicarbonate in 6 hours of cultivation by the present method technologies in contrast to the existing method has a positive effect on the production of PA, antigenic activity of which 12 hours of cultivation goes on regulated show the eh 100 EA· ml-1and to 19 hours growth antigenic activity increases up to 200 EA·ml-1and remains at this level until the end of the cultivation process.

Example 2. Selection of efficient equipment in the process of obtaining sterile concentrated PA.

The use of ultra - and microfiltration installation "Cartoon" in the process of selection, sterilization and concentration of PA allows to:

to conduct the process under aseptic conditions;

to carry out sterilization equipment chemical and thermal methods and their combination that meets the requirements of GMP;

quickly replace filter elements in case of failure during the process thanks to the modular filter system installation "Sartocon".

The inventive method of obtaining sterile concentrated PA using installation "Sartocon" during the process of micro - and ultrafiltration reduces the number of stages from 6 to 2, reduces the time allocation of PA from the culture fluid and the whole cycle as a whole compared with the existing method, and includes:

the allocation of PA from the culture fluid and simultaneous sterilization;

the concentration of sterile PA.

Technological characteristics of the process of concentri the Finance PA on existing and declared the ways technologies is presented in table 3.

As can be seen from the data presented in table 3, the use of micro - and ultrafiltration installation "Sartocon" the claimed method significantly reduces the time allocation of PA from the culture fluid and the whole technological process as a whole compared with the existing method of technology.

Table 1
Dynamics of microbial culture according to the existing method, n=5
Defined index The cultivation, h
0 9 12 15 18 20
pH, pH units 8,4 8,1 7,7 7,6 7,4 7,0
Biomass units ex. 60 250 280 350 560 1300
The utilization of glucose, % 0 5 18 28 43 68
Antigenic activity in the RDP, EA. ml-1 0 25 25 25...50 25...50 25...100

Table 2
Dynamics of microbial culture by the present method, p=10
Defined index The cultivation, h
0 6 12 19
pH, pH units 7,7 7,2/7,9* 7,6 7,4
Biomass units ex. 75 650 1480 1860
The utilization of glucose, % 0 16 79 100
Antigenic activity in the RDP, EA. ml-1 0 0 50...100 100...200
Note: * - the value of pH of the culture before and after the introduction of sodium bicarbonate.

Table 3
The temporal characteristics of the technological process on the existing and the proposed method, n=3
The stage of the technological process on the existing method During the process, according to the existing method, min The stage of the technological process as claimed method During the process claimed is the procedure, min
The allocation of PA from the culture fluid by the method of separation "Westfalia" SA-02-575 90±10 The allocation of PA from native culture and its simultaneous sterilization microfiltration at the "Santacon-2" 40±10
The concentration of native PA on installing UFS -0,4 90±20 The concentration of sterile PA by ultrafiltration at the "Santacon-2". 40±10
The coarse filtration (suction flask) 120±10 no no
Fine filtration, filter IFA-And No. 2 60±10 no no
Sterilizing filtration, filter IFA-And No. 1 60±10 no no
The total duration of the existing method is 420±20 minutes The total duration of the proposed method is 80±10 minutes

The method of obtaining the anthrax protective antigen, including the cultivation of vaccine strain of sterile nutrient medium with sodium bicarbonate, wherein the sodium bicarbonate is lead into the nutrient medium during the exponential phase of growth at 6-8 h of cultivation vaccine strain, and after the end of the cultivation process selection, concentration and sterilization protective antigen carried out on a single installation of ultra - and microfiltration.

 

© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.